N-propeptide type I collagen

a 24 kDa bone phosphoprotein; the amino propeptide extension of type I collagen alpha 1 chains

Also Known As:

aminoterminal telopeptide of type I collagen; collagen, N-propeptide type I-; propeptide-aI-I-collagen

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Scleroproteins: 74
    - Extracellular Matrix Proteins: 3148
      - Collagen: 52417
        Procollagen: 1361
        N-propeptide type I collagen: 4
  - Protein Precursors: 37
    - Procollagen: 1361
      - N-propeptide type I collagen: 4
- Peptides: 82426
  - Phosphopeptides: 367
    - N-propeptide type I collagen: 4

Experts

1.	Azinge, E C: 1 article (09/2010)
2.	Bolarin, D M: 1 article (09/2010)
3.	Dunkel, Leo: 1 article (01/2009)
4.	Hero, Matti: 1 article (01/2009)
5.	Kröger, Heikki: 1 article (01/2009)
6.	Mäkitie, Outi: 1 article (01/2009)
7.	Nousiainen, Elina: 1 article (01/2009)
8.	Toiviainen-Salo, Sanna: 1 article (01/2009)
9.	Ikeda, Noriko: 1 article (12/2002)
10.	Miyoshi, Yasuo: 1 article (12/2002)

Related Diseases

1.	Bone Resorption 01/01/2009 - "In letrozole-treated boys, the concentrations of the bone resorption marker urine aminoterminal telopeptide of type I collagen initially increased and thereafter slowly declined while the concentrations of the bone formation markers serum aminoterminal propeptide of type I collagen and serum alkaline phosphatase remained unchanged or slightly increased, respectively. " 12/05/2002 - "BMD of the lumbar supine (dual emission X-rays absorptiometry) and bone resorption (deoxypyridinoline, aminoterminal telopeptide of type I collagen, and carboxyterminal telopeptide of type I collagen) and formation (propeptide of type I procollagen, osteocalcin, and bone-specific alkaline phosphatase) markers were examined at baseline (before the surgery), 6 and 12 months after the start of tamoxifen treatment. " 04/01/1998 - "We compared here the effects of tamoxifen and toremifene on bone metabolism and density in 30 postmenopausal patients with breast cancer, who were randomized to receive tamoxifen (20 mg/day, n = 16) or toremifene (40 mg/day, n = 14) for 1 yr. Biochemical markers of bone resorption [urinary hydroxyproline, serum cross-linked carboxyterminal telopeptide of type I collagen, urinary cross-linked aminoterminal telopeptide of type I collagen (NTx)] and bone formation [serum bone-specific alkaline phosphatase, osteocalcin, and aminoterminal and carboxyterminal propeptide of type I procollagen] were assessed before treatment and at 6 and 12 months of the antiestrogen regimen. "
2.	Breast Neoplasms (Breast Cancer) 04/01/1998 - "We compared here the effects of tamoxifen and toremifene on bone metabolism and density in 30 postmenopausal patients with breast cancer, who were randomized to receive tamoxifen (20 mg/day, n = 16) or toremifene (40 mg/day, n = 14) for 1 yr. Biochemical markers of bone resorption [urinary hydroxyproline, serum cross-linked carboxyterminal telopeptide of type I collagen, urinary cross-linked aminoterminal telopeptide of type I collagen (NTx)] and bone formation [serum bone-specific alkaline phosphatase, osteocalcin, and aminoterminal and carboxyterminal propeptide of type I procollagen] were assessed before treatment and at 6 and 12 months of the antiestrogen regimen. "
3.	Sickle Cell Anemia (Hemoglobin S Disease) 09/01/2010 - "The determination of the following new biochemical markers of bone metabolism has not been previously performed in sickle cell disease: serum osteocalcin (S-BGP), urinary cross-linked aminoterminal telopeptide of type I collagen (INTP or NTx) and urinary deoxypyridinoline (U∼DPD). "

Related Drugs and Biologics

1.	Collagen Type I (Type I Collagen)
2.	Osteocalcin
3.	Biomarkers (Surrogate Marker)
4.	Alkaline Phosphatase
5.	Tamoxifen
6.	deoxypyridinoline
7.	Procollagen Type I
8.	Estrogen Receptor Modulators (Antiestrogen)
9.	Toremifene (Fareston)
10.	Hydroxyproline (4 Hydroxyproline)